Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/33089

Efectividad y seguridad de la dapagliflozina en pacientes con diabetes mellitus tipo 1. Revisión bibliográfica sistemática


Vista previa

Ver/Abrir:
 Sánchez Casanova,Inés.pdf

1,45 MB
Adobe PDF
Compartir:
Título :
Efectividad y seguridad de la dapagliflozina en pacientes con diabetes mellitus tipo 1. Revisión bibliográfica sistemática
Autor :
Sánchez Casanova, Inés
Tutor:
Picó Monllor, José Antonio
Editor :
Universidad Miguel Hernández
Departamento:
Departamentos de la UMH::Farmacología, Pediatría y Química Orgánica
Fecha de publicación:
2024-05-23
URI :
https://hdl.handle.net/11000/33089
Resumen :
OBJETIVO: Revisar la literatura científica disponible sobre la efectividad y seguridad de la dapagliflozina en pacientes con diabetes mellitus tipo 1. MÉTODO: Revisión bibliográfica sistemática de la literatura científica recogida en las bases de datos The Cochrane Library, Embase, MEDLINE (vía Pub...  Ver más
OBJECTIVE: To review the available scientific literature on the effectiveness and safety of dapagliflozin in patients with type 1 diabetes mellitus. METHOD: Systematic review of scientific literature gathered from The Cochrane Library, Embase, MEDLINE (via PubMed), Scopus, and Web of Science databases until March 2024. The search equation was conducted using the descriptors “Diabetes Mellitus, Type 1”, "SodiumGlucose Transporter 2 Inhibitors” and "Diabetic ketoacidosis” along with a query of the title and abstract fields with free terms. The quality of the articles was evaluated using the CONSORT guidelines. RESULTS: Out of 177 references retrieved, after applying inclusion and exclusion criteria, 11 articles were selected for review. The studies observed multiple benefits such as reduction in glycosylated hemoglobin and body weight, along with adverse effects such as diabetic ketoacidosis. CONCLUSION: The use of dapagliflozin in type 1 diabetes offers potential benefits in glycemic control, weight loss, and quality of life, despite the associated risks of diabetic ketoacidosis. With careful evaluation and monitoring to avoid DKA, it could be a valuable therapeutic option for some patients, especially those not satisfied with conventional treatments. However, additional longterm studies are needed to confirm its effectiveness and safety, as well as more research on DKA to establish an optimal prevention protocol.
Palabras clave/Materias:
Diabetes Mellitus tipo 1
Dapagliflozina
Inhibidores de SGLT2
Cetoacidosis diabética
Type 1 Diabetes Mellitus
Dapagliflozin
SGLT2 Inhibitors
Diabetic Ketoacidosis
Área de conocimiento :
CDU: Ciencias aplicadas: Medicina: Farmacología. Terapéutica. Toxicología. Radiología
Tipo de documento :
info:eu-repo/semantics/bachelorThesis
Derechos de acceso:
info:eu-repo/semantics/openAccess
Aparece en las colecciones:
TFG - Farmacia



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.